Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up

Daiichi Sankyo’s core operating profit rose 46.9% year over year to ¥221.3 billion in the six months ended Sept. 30, while revenue increased 19.7% to ¥1.17 trillion; oncology revenue surged 54.8% to ¥422.6 billion. The company maintained its fiscal 2026 forecasts, including ¥2.34 trillion in revenue and ¥360 billion in core operating profit, and plans to raise its annual dividend to ¥100 per share from ¥78. Shares rose 3.7% to ¥2,714.5 by 04:56 GMT.

Analysis

The more investable read-through is the economics of the Daiichi Sankyo–AstraZeneca partnership, not Daiichi Sankyo’s headline growth: higher profit-sharing payments are a positive signal for AstraZeneca’s partnered-product revenue, but do not establish the net profit contribution or its materiality to AstraZeneca’s consolidated results. Confirm the effect in AstraZeneca’s disclosures before assigning earnings value.

Daiichi Sankyo’s unchanged full-year outlook tempers the strong half-year result. The reported contribution from FX and the faster-growing oncology portfolio may not translate one-for-one into a forecast increase; rising R&D and partner payments also absorb growth. A reversal in yen weakness would remove a reported revenue tailwind, while reliance on a concentrated oncology portfolio raises product, safety, and competitive-substitution risk over the 6–18 month horizon.

Near term, the share reaction may reward the earnings beat, but the lack of guidance uplift makes follow-through dependent on evidence that demand and margins support the annual target. For AstraZeneca, the read-through is directionally positive but insufficient on its own to justify a material estimate change. The contrarian risk is treating sales growth as equivalent to retained earnings after collaboration economics. No standalone trade is warranted without valuation, product-level contribution, and AstraZeneca disclosure detail.

Key Decisions for Investors

• AstraZeneca: treat the partner-payment increase as a watch item, not an earnings upgrade. Verify product-level revenue/profit-sharing disclosures and the net contribution at the next reporting update before adding exposure.
• Daiichi Sankyo: avoid extrapolating first-half core profit growth into a full-year beat while guidance remains unchanged. Reassess if management raises or cuts the annual core operating profit outlook, or if oncology demand/margins diverge from plan.
• Monitor yen moves and oncology product updates over the next 1–3 months. A material yen reversal, adverse safety/regulatory news, or evidence of competitive substitution would weaken the growth read-through; sustained demand plus improved guidance would strengthen it.
• No immediate pair trade: the article provides no valuation comparison or quantified AstraZeneca earnings contribution. Revisit only after those inputs are available.